Sulfinpyrazone
Sulfinpyrazone is a uricosuric agent and antiplatelet drug used for the treatment of hyperuricemia and chronic gout by inhibiting tubular reabsorption of uric acid in the kidney, increasing renal uric acid excretion and lowering serum urate levels. It also inhibits platelet cyclooxygenase and thromboxane synthesis, with antiplatelet properties that were investigated for prevention of thromboembolic events. It is used as an alternative to probenecid in patients intolerant of allopurinol.
Khối lượng phân tử
404,5000 g/mol
LogP
2,30
TPSA
76,90 Ų
Lipinski RO5
Đạt
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Cấu trúc 2D
Cite this structure
Embed this structure
SMILES
O=C1C(CC[S+]([O-])c2ccccc2)C(=O)N(c2ccccc2)N1c1ccccc1
InChI
InChI=1S/C23H20N2O3S/c26-22-21(16-17-29(28)20-14-8-3-9-15-20)23(27)25(19-12-6-2-7-13-19)24(22)18-10-4-1-5-11-18/h1-15,21H,16-17H2
Molecular Formula
C23H20N2O3S
HBD / HBA
- / 4
Liên kết có thể quay
6
Nguyên tử nặng
29
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Câu hỏi thường gặp
Sulfinpyrazone is a uricosuric agent and antiplatelet drug used for the treatment of hyperuricemia and chronic gout by inhibiting tubular reabsorption of uric acid in the kidney, increasing renal uric acid excretion and lowering serum urate levels. It also inhibits platelet cyclooxygenase and thromboxane synthesis, with antiplatelet properties that were investigated for prevention of thromboembolic events. It is used as an alternative to probenecid in patients intolerant of allopurinol.
Yes, Sulfinpyrazone is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL832. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 5342. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="sulfinpyrazone"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/sulfinpyrazone/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/sulfinpyrazone/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/sulfinpyrazone/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="sulfinpyrazone"></drugfyi-drug>